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Psychopharmacology for the Clinician

The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients
with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this
column is a composite with characteristics of several real patients.

Pharmacotherapy of
trichotillomania
Verinder Sharma, MBBS

A 27-year old woman with a history of
bipolar II disorder was referred with a
history of nonresponse to 2 adequate
trials of antidepressants for the index
episode of depression. During a routine inquiry to assess symptoms of
obsessive–compulsive disorder (OCD),
she reported a history of recurrent
pulling of hair from her scalp and her
eyebrows, also known as trichotillomania (TTM), since the birth of her
only child 8 months earlier. Symptoms
of TTM persisted despite the patient’s
repeated attempts to stop the behaviour and treatment with antidepressants. She denied having had any obsessions or compulsions before the
onset of TTM, but she reported having
experienced panic attacks on occasion.
Her family history was positive for
postpartum depression and OCD in
her mother. The patient was physically
healthy, and recent blood work confirmed normal thyroid function.
The patient met the DSM-5 diagnostic criteria for bipolar II disorder with
peripartum onset and TTM. Citalopram was tapered off owing to its lack
of effectiveness for both bipolar disorder and TTM. Lithium was recommended owing to its efficacy in the
acute treatment of bipolar II depression. The patient was started on
300 mg daily, and the dose was eventually optimized to 750 mg, attaining a
serum level of 0.67 mmol/L. At the
3-month follow-up visit, symptoms of
both depression and TTM had fully
remitted. The patient has remained
symptom-free for 1 year and continues
to take 750 mg of lithium daily.
Trichotillomania is no longer con
sidered an impulse disorder; it has been
reclassified as an obsessive–compulsive
and related disorder (OCRD) in DSM-

5.1 Although DSM-5 does not allow the
use of the “with p
 eripartum onset”
specifier to characterize OCRD, it acknowledges that “onset or exacerbation
of obsessive–compulsive disorder, as
well as symptoms that can interfere
with the mother–infant relationship,
have been reported in the postpartum
period.” Trichotillomania can be debilitating; however, patients are reluctant
to seek help owing to feelings of shame
and embarrassment. Onset is typically
during early adolescence, but there are
occasional reports of onset after childbirth. The disorder commonly occurs
comorbidly with major depression,
anxiety disorders and substance use
disorders and occasionally with bipolar
II disorder.
Patients presenting with TTM should
undergo thorough psychiatric assessment for diagnostic confirmation
and psychiatric comorbidity.2 Medical
evaluation is indicated for patients with
a history of swallowing hair after pulling, also known as trichophagia. As
TTM impacts psychosocial functioning
and quality of life, patients should be
assessed for self-esteem, social interaction, participation in recreational activ
ities and work productivity.3
Currently there are no treatments
for TTM approved by the US Food
and Drug Administration, which
poses a challenge for physicians when
selecting appropriate pharmacotherapy. Drugs from different classes have
been studied, including antidepressants, anticonvulsants, central nervous
system stimulants, glutamate modulators, opioid antagonists and neuroleptics.4,5 Early studies focused on serotonin reuptake inhibitors; however,
there is no clear evidence of their effect
iveness in the treatment of TTM. Nacetylcysteine (NAC), a glutamatergic
agent, has also been studied. A recent
systematic review of 4 randomized,
double-blind placebo-controlled trials
on the use of NAC in the treatment of

TTM found inconclusive evidence, but
suggested that NAC may still be useful as a treatment for OCRD owing to
its relatively benign side effect profile.5,6 There are occasional reports on
the use of lithium that suggest the
drug may be effective in patients with
comorbid bipolar disorder.7,8 Regarding psychotherapy, behavioural therapy, specifically habit reversal therapy
and group cognitive-behavioural therapy, may be beneficial.9
In the absence of clear guidance
about the choice of appropriate
drugs, selection of medication should
take into consideration factors such as
the severity of the disorder, psychi
atric comorbidity and timing of the
onset of TTM. 10 There is emerging
e vidence that psychiatric disorders
with postpartum onset are possibly
early manifestations of bipolar dis
order.11,12 Early recognition and appropriate treatment of bipolar dis
order in these patients may help
prevent the harmful consequences of
both bipolar disorder and TTM.
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